Elekta AB (EKTABN) Stock Price & Analysis
EKTABN Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- MXN 43.61B
- Enterprise Value
- MXN 23.05B
- Total Cash (Recent Filing)
- MXN 2.31B
- Total Debt (Recent Filing)
- MXN 6.83B
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Nov 25, 2026 (Est.)
- EPS Estimate
- 1.61
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Service Base
Elekta’s installed base creates recurring service, maintenance, and upgrade demand beyond the initial equipment sale. Because radiation therapy systems have long operating lifecycles, this model can support customer retention, revenue visibility, and ongoing monetization over several years.
Free Cash Flow
Strong recent operating and free cash flow provides internal funding for service delivery, product development, and customer support while reducing reliance on external financing. The improvement versus prior years is a meaningful counterweight to current earnings pressure and supports near-term financial resilience.
Stable Gross Margin
A gross margin that remains around 37% indicates that Elekta continues to retain substantial economic value in its products and services even during weaker revenue conditions. This underlying margin base could support recovery if volumes and operating leverage improve over the coming quarters.
Bears Say
Revenue And Earnings Decline
The sharp revenue contraction and shift to a net loss weaken the company’s earnings foundation and can reduce resources available for innovation, investment, and shareholder returns. A sustained decline would also make it harder to absorb fixed costs and restore prior profitability.
Higher Leverage
Higher debt relative to equity and a shrinking equity base have reduced Elekta’s balance-sheet flexibility. This can constrain capital allocation and increase sensitivity to weaker operating results, while limiting the company’s ability to fund growth or withstand prolonged financial underperformance.
Operating Margin Compression
The substantial decline in EBIT margin shows that operating costs are consuming more of each sales dollar as revenue weakens. Unless Elekta restores operating leverage, lower margins can limit profit recovery even if gross margin remains stable and cash generation stays positive.
Elekta AB News
EKTABN FAQ
What is Elekta AB’s market cap?
When is Elekta AB’s upcoming earnings report date?
How were Elekta AB’s earnings last quarter?
Is Elekta AB overvalued?
Does Elekta AB pay dividends?
What is Elekta AB’s EPS estimate?
How many shares outstanding does Elekta AB have?
What happened to Elekta AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Elekta AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Elekta AB
Elekta AB (publ) operates as a global medical technology company, delivering advanced clinical solutions for managing cancer and various brain disorders. Its extensive oncology offerings include sophisticated radiation therapy systems such as Versa HD, tailored for brain metastases; the groundbreaking Elekta Unity, leveraging MR-Linac technology; linear accelerators like Elekta Harmony; and Elekta Infinity, designed to address diverse radiotherapy needs. The company also provides Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy. Beyond primary treatment devices, Elekta supplies comprehensive treatment management solutions, automated and integrated quality assurance tools, and hardware/software for motion management. Specialized oncology platforms feature MOSAIQ Plaza for multidisciplinary cancer care, the managed hosting service Elekta Axis Cloud, and Elekta Studio for image-guided brachytherapy. Complementary hardware includes the ImagingRing mobile CT scanner. For brachytherapy, they offer smart tools like Oncentra Brachy to streamline repetitive tasks, alongside applicators such as Venezia and Geneva for cervical cancer treatment, and the Elekta Flexitron afterloader for precise workflow execution. In the field of neurosurgery and radiosurgery, Elekta provides the Leksell Gamma Knife series, including Icon for personalized radiation treatment, Perfexion as a vital tool for neurosurgeons, and Lightning for accelerated radiosurgery. Their neurosurgery product line further encompasses the Leksell Vantage Stereotactic System for intracranial procedures and the Leksell Stereotactic System for minimally invasive interventions. Elekta AB (publ) was founded in 1972 and is headquartered in Stockholm, Sweden.
- Sector
- General
- Industry
- Medical - Devices
- CEO
- Jakob Just-Bomholt
- Employees
- 3,996
- Website
- www.elekta.com
- Address
- Hagaplan 4, Stockholm, SD, 113 68, SE









